Donneurs de tissus : Questions médicales fréquentes
Nom anglais: Tissue Donors
Descriptor UI:D014019
Tree Number:M01.898
Termes MeSH sélectionnés :
Cholangiocarcinoma
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Donneurs de tissus : Questions médicales les plus fréquentes",
"headline": "Donneurs de tissus : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Donneurs de tissus : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-04-09",
"dateModified": "2025-04-04",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Donneurs de tissus"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Personnes",
"url": "https://questionsmedicales.fr/mesh/D009272",
"about": {
"@type": "MedicalCondition",
"name": "Personnes",
"code": {
"@type": "MedicalCode",
"code": "D009272",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Donneurs de sang",
"alternateName": "Blood Donors",
"url": "https://questionsmedicales.fr/mesh/D001782",
"about": {
"@type": "MedicalCondition",
"name": "Donneurs de sang",
"code": {
"@type": "MedicalCode",
"code": "D001782",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01.898.313"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Donneur vivant",
"alternateName": "Living Donors",
"url": "https://questionsmedicales.fr/mesh/D019520",
"about": {
"@type": "MedicalCondition",
"name": "Donneur vivant",
"code": {
"@type": "MedicalCode",
"code": "D019520",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01.898.656"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Donneurs non apparentés",
"alternateName": "Unrelated Donors",
"url": "https://questionsmedicales.fr/mesh/D061349",
"about": {
"@type": "MedicalCondition",
"name": "Donneurs non apparentés",
"code": {
"@type": "MedicalCode",
"code": "D061349",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "M01.898.828"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Donneurs de tissus",
"alternateName": "Tissue Donors",
"code": {
"@type": "MedicalCode",
"code": "D014019",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Melissa A Greenwald",
"url": "https://questionsmedicales.fr/author/Melissa%20A%20Greenwald",
"affiliation": {
"@type": "Organization",
"name": "American Association of Tissue Banks, McLean, Virginia, USA."
}
},
{
"@type": "Person",
"name": "Sujata Das",
"url": "https://questionsmedicales.fr/author/Sujata%20Das",
"affiliation": {
"@type": "Organization",
"name": ""
}
},
{
"@type": "Person",
"name": "Claus Cursiefen",
"url": "https://questionsmedicales.fr/author/Claus%20Cursiefen",
"affiliation": {
"@type": "Organization",
"name": "Zentrum für Augenheilkunde, Uniklinik Köln."
}
},
{
"@type": "Person",
"name": "Namrata Sharma",
"url": "https://questionsmedicales.fr/author/Namrata%20Sharma",
"affiliation": {
"@type": "Organization",
"name": "Cornea, Cataract and Refractive Services, Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India."
}
},
{
"@type": "Person",
"name": "Sabine Salla",
"url": "https://questionsmedicales.fr/author/Sabine%20Salla",
"affiliation": {
"@type": "Organization",
"name": "Department of Ophthalmology, RWTH Aachen University, Pauwelsstr. 30, 52074 Aachen, Germany."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Pathological survey of precursor lesions in cholangiocarcinoma.",
"datePublished": "2023-02-18",
"url": "https://questionsmedicales.fr/article/36707055",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/jhbp.1308"
}
},
{
"@type": "ScholarlyArticle",
"name": "Prognostic factors in patients with intrahepatic cholangiocarcinoma.",
"datePublished": "2024-08-17",
"url": "https://questionsmedicales.fr/article/39154139",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1038/s41598-024-70124-z"
}
},
{
"@type": "ScholarlyArticle",
"name": "Expression and molecular insights of lima1 in cholangiocarcinoma.",
"datePublished": "2024-07-30",
"url": "https://questionsmedicales.fr/article/39076043",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1080/19336918.2024.2383068"
}
},
{
"@type": "ScholarlyArticle",
"name": "Effect of age on the prognosis of intrahepatic cholangiocarcinoma.",
"datePublished": "2022-12-21",
"url": "https://questionsmedicales.fr/article/36541019",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3904/kjim.2022.146"
}
},
{
"@type": "ScholarlyArticle",
"name": "Cholangiocarcinoma: Epidemiology and Imaging-Based Review.",
"datePublished": "2024-05-02",
"url": "https://questionsmedicales.fr/article/38687269",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": null
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Personnes",
"item": "https://questionsmedicales.fr/mesh/D009272"
},
{
"@type": "ListItem",
"position": 3,
"name": "Donneurs de tissus",
"item": "https://questionsmedicales.fr/mesh/D014019"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Donneurs de tissus - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Donneurs de tissus",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-09",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Donneurs de tissus",
"description": "Comment évaluer la compatibilité des tissus ?\nQuels tests sont effectués sur les donneurs ?\nQuand un donneur est-il considéré comme inéligible ?\nQuelles sont les indications pour le don de tissus ?\nComment se déroule l'évaluation médicale d'un donneur ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Donneurs de tissus",
"description": "Quels symptômes peuvent indiquer un problème de don ?\nY a-t-il des effets secondaires après le don de tissus ?\nComment reconnaître une infection post-don ?\nQuels signes d'alerte après un don de tissus ?\nLes donneurs ressentent-ils des douleurs après le don ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Donneurs de tissus",
"description": "Comment prévenir les infections après un don ?\nQuelles précautions prendre avant de donner des tissus ?\nComment se préparer à un don de tissus ?\nY a-t-il des vaccinations recommandées pour les donneurs ?\nComment éviter les complications après le don ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Donneurs de tissus",
"description": "Quels traitements sont disponibles pour les donneurs ?\nComment gérer la douleur après le don ?\nY a-t-il un suivi médical après le don ?\nQuels soins sont nécessaires après un don de tissus ?\nLes donneurs ont-ils besoin de réhabilitation ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Donneurs de tissus",
"description": "Quelles sont les complications possibles du don de tissus ?\nComment reconnaître une complication après le don ?\nLes complications sont-elles fréquentes ?\nQue faire en cas de complication après le don ?\nLes complications peuvent-elles affecter la santé future ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Donneurs de tissus",
"description": "Quels sont les facteurs de risque pour les donneurs ?\nComment les antécédents médicaux influencent-ils le don ?\nLes infections antérieures affectent-elles le don ?\nQuels comportements augmentent les risques pour les donneurs ?\nLes donneurs âgés ont-ils plus de risques ?",
"url": "https://questionsmedicales.fr/mesh/D014019?mesh_terms=Cholangiocarcinoma&page=4#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment évaluer la compatibilité des tissus ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "La compatibilité est évaluée par des tests de typage tissulaire et de groupes sanguins."
}
},
{
"@type": "Question",
"name": "Quels tests sont effectués sur les donneurs ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests sanguins pour les infections et des évaluations de santé générale sont réalisés."
}
},
{
"@type": "Question",
"name": "Quand un donneur est-il considéré comme inéligible ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un donneur est inéligible s'il a des infections transmissibles ou des maladies graves."
}
},
{
"@type": "Question",
"name": "Quelles sont les indications pour le don de tissus ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les indications incluent les greffes de cornée, de peau, et de tissus osseux."
}
},
{
"@type": "Question",
"name": "Comment se déroule l'évaluation médicale d'un donneur ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'évaluation comprend un examen physique et un historique médical détaillé."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème de don ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes comme la fièvre, la fatigue ou des douleurs peuvent alerter."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires après le don de tissus ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des effets secondaires peuvent inclure des douleurs au site de prélèvement ou des infections."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une infection post-don ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une infection peut se manifester par rougeur, chaleur, ou écoulement au site de prélèvement."
}
},
{
"@type": "Question",
"name": "Quels signes d'alerte après un don de tissus ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une douleur intense ou une fièvre élevée nécessitent une consultation médicale."
}
},
{
"@type": "Question",
"name": "Les donneurs ressentent-ils des douleurs après le don ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une douleur légère à modérée est courante, mais elle doit être surveillée."
}
},
{
"@type": "Question",
"name": "Comment prévenir les infections après un don ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Il est essentiel de garder le site propre et de suivre les instructions médicales."
}
},
{
"@type": "Question",
"name": "Quelles précautions prendre avant de donner des tissus ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Évitez les médicaments anticoagulants et informez le médecin de votre état de santé."
}
},
{
"@type": "Question",
"name": "Comment se préparer à un don de tissus ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivez les recommandations médicales, hydratez-vous et reposez-vous avant le don."
}
},
{
"@type": "Question",
"name": "Y a-t-il des vaccinations recommandées pour les donneurs ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des vaccinations contre certaines infections peuvent être recommandées avant le don."
}
},
{
"@type": "Question",
"name": "Comment éviter les complications après le don ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Suivez les instructions médicales et signalez tout symptôme inhabituel rapidement."
}
},
{
"@type": "Question",
"name": "Quels traitements sont disponibles pour les donneurs ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des analgésiques et des soins pour le site de prélèvement."
}
},
{
"@type": "Question",
"name": "Comment gérer la douleur après le don ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "La douleur peut être gérée avec des médicaments prescrits et des soins appropriés."
}
},
{
"@type": "Question",
"name": "Y a-t-il un suivi médical après le don ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, un suivi médical est recommandé pour surveiller la récupération et prévenir les complications."
}
},
{
"@type": "Question",
"name": "Quels soins sont nécessaires après un don de tissus ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des soins incluent le nettoyage du site et l'observation des signes d'infection."
}
},
{
"@type": "Question",
"name": "Les donneurs ont-ils besoin de réhabilitation ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "La réhabilitation est rarement nécessaire, mais peut être recommandée en cas de complications."
}
},
{
"@type": "Question",
"name": "Quelles sont les complications possibles du don de tissus ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications peuvent inclure des infections, des saignements ou des réactions allergiques."
}
},
{
"@type": "Question",
"name": "Comment reconnaître une complication après le don ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme une douleur accrue, une rougeur ou un gonflement peuvent indiquer une complication."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles fréquentes ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications sont rares mais peuvent survenir, nécessitant une attention médicale."
}
},
{
"@type": "Question",
"name": "Que faire en cas de complication après le don ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Consultez immédiatement un professionnel de santé si vous suspectez une complication."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la santé future ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent avoir des effets à long terme, mais cela reste rare."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les donneurs ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des antécédents médicaux, des infections et des comportements à risque."
}
},
{
"@type": "Question",
"name": "Comment les antécédents médicaux influencent-ils le don ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des antécédents de maladies graves peuvent rendre un individu inéligible au don."
}
},
{
"@type": "Question",
"name": "Les infections antérieures affectent-elles le don ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines infections antérieures peuvent compromettre la sécurité du don."
}
},
{
"@type": "Question",
"name": "Quels comportements augmentent les risques pour les donneurs ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des comportements comme l'usage de drogues ou des rapports sexuels non protégés augmentent les risques."
}
},
{
"@type": "Question",
"name": "Les donneurs âgés ont-ils plus de risques ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "L'âge avancé peut être un facteur de risque, mais chaque cas est évalué individuellement."
}
}
]
}
]
}
To clarify the pathological significance of two precursors (high-grade biliary intraepithelial neoplasm [BilIN] and intraductal papillary neoplasm of bile duct [IPNB]) in cholangiocarcinomas (CCAs)....
Ninety-one cases of CCA (47 distal CCAs [dCCAs], 31 perihilar CCAs [pCCAs] and 13 intrahepatic CCAs of large duct type [LD-iCCAs]) were examined for their association with precursors. Neoplastic intra...
Fifty-four and 8 of 91 CCAs were associated with high-grade BilIN and IPNB, respectively, while these precursors were unidentifiable in the remaining CCAs. A majority of CCAs were of the gastrobiliary...
CCAs were frequently associated with precursors; high-grade BilIN may be a major precursor and IPNB a minor one. CCAs with IPNB showed a favorable postoperative OS compared to CCAs with high-grade Bil...
Intrahepatic cholangiocarcinoma (ICC) is the second commonly-seen liver malignancy and one of the most fatal cancers in Taiwan. Survival after diagnosis of ICC remains poor. This study aimed to invest...
Lim Domain and Actin Binding protein1 (lima1) influence cancer cell function. Thus far, functional role of lima1 in cholangiocarcinoma remains unknown. We used public databases, in vitro experiments, ...
Intrahepatic cholangiocarcinoma (iCCA) is a subgroup of cholangiocarcinoma and is the second- most-common primary hepatic tumor. Several predictive and prognostic factors have been analyzed; however, ...
A retrospective analysis of patients treated between 2005 and 2016 at Konkuk University Medical Center. In total, 133 patients with iCCA were identified. The mass-forming, periductal-infiltrating, and...
In total, 114 patients were enrolled. The two groups differed with regard to treatment options such as surgery with adjuvant chemotherapy or palliative chemotherapy (p = 0.012, p < 0.001). The younger...
Younger patients and those who underwent surgery with adjuvant chemotherapy had longer survival. The younger the patient, the more treatments received, including palliative chemotherapy....
Cholangiocarcinoma (CCA) is a rare cancer of the bile duct epithelium, and in the last few decades its incidence rate has been increasing. It is associated with a high mortality rate due to late diagn...
Hilar cholangiocarcinoma is considered a biologically aggressive disease for which surgical resection remains the only curative treatment. Preoperative evaluation for resectability is challenging give...
The survival rate of patients with irresectable perihilar cholangiocarcinoma is remarkably poor. An essential part of palliation is treatment of obstructive cholestasis caused by the tumor. Currently,...
Between 2005 and 2016, we treated 120 pCCC patients with primary palliative care. Three treatment strategies were retrospectively considered: extrahepatic bile duct resection (EBR), exploratory laparo...
The EBR group required significantly less stenting postoperatively, and the overall morbidity was 29.4% (EBR). After the surgical procedure, fewer subsequent endoscopic treatments for stenting or PTBD...
In selected pCCC patients, palliative extrahepatic bile duct resection is a feasible option for treatment of obstructive cholestasis and should be reconsidered as a therapy option for these patients e...
Intrahepatic cholangiocarcinoma (ICC) is a malignant tumor, which poses a serious threat to human health. Histone 3 lysine 9 trimethylation (H3K9me3) is a post-translational modification involved in r...
In this study, we applied the ChIP-seq technique to investigate the effect of H3K9me3 on ICC. Anti-H3K9me3 antibody was used for ChIP-seq in ICC (RBE cell lines) and HIBEpic (normal cell lines). MACS2...
H3K9me3 exhibited abnormal methylation and influenced the process of abnormal gene expression in patients suffering from ICC. The Wnt/β-Catenin signaling pathway (also known as simply the WNT signalin...
We are the first to report that H3K9me3 may play an important role in the progression of ICC. It promotes the understanding of epigenetic molecular mechanisms for ICC....
Cholangiocarcinoma (CCA) is a group of malignancies of the bile ducts with high mortality rates and limited treatment options. In the past decades, remarkable efforts have been dedicated toward elucid...
Cholangiocarcinoma is a rare tumor but a challenging cancer in terms of pathological changes, clinical manifestations and therapeutic options. Recent studies have provided evidence for participation o...